Overcoming Fill-Finish Capacity Bottlenecks in Automated Pen Injector Assembly Lines

The global shift toward self-administration of biologics has driven the exponential demand for pen injectors.1 For pharmaceutical manufacturers and CDMOs, scaling up production to meet this demand requires robust automated assembly lines. While individual machines may boast high theoretical throughput, the overall equipment effectiveness (OEE) often suffers due to micro-stoppages, component variations, and integration complexities between pre-assembly and final assembly stages.2

Addressing these bottlenecks requires a holistic systems-engineering approach, focusing on the seamless integration of pre-filled syringe (PFS) handling, dosing mechanism assembly, and rigorous quality control at high speeds.

Challenge 1: Component Variability and High-Speed Feeding

One of the primary causes of micro-stoppages in high-speed assembly lines, operating at 100-160 parts per million (PPM), is the dimensional variability of molded plastic components.2 Even minor deviations within acceptable tolerances can lead to jamming in vibratory bowl feeders or misalignment during robotic pick-and-place operations.

Engineering Solution: To mitigate this, advanced assembly lines must employ adaptive feeding systems. Utilizing vision-guided robotics for component orientation rather than relying solely on mechanical sorting significantly reduces jam rates. Furthermore, implementing continuous-motion assembly architectures, in which components are assembled on a moving turret rather than intermittent indexing systems, provides smoother handling of fragile parts and accommodates slight dimensional variations without halting production.3

Challenge 2: Precision Alignment in Final Assembly

The final assembly of a pen injector, in which the drug cartridge or pre-filled syringe is integrated with the dosing mechanism, is the most critical phase. The alignment must be perfect to ensure the dose accuracy and the mechanical integrity of the device. Misalignment not only damages the glass cartridge, leading to costly product loss, but also poses severe safety risks to the end-user.

Engineering Solution: Achieving precision at 160 PPM requires moving beyond standard pneumatic actuators. Servo-driven pressing stations equipped with force-displacement monitoring provide the necessary control.5 By continuously monitoring the force profile during the pressing operation, the system can detect anomalies, such as a slightly oversized cartridge or a misaligned thread, in milliseconds. If the force profile deviates from the validated parameters, the system can abort the operation before glass breakage occurs, rejecting the specific unit without stopping the entire line.

Challenge 3: Seamless Integration of Pre-Assembly and Final Assembly

Many manufacturers procure pre-assembly equipment and final assembly equipment from different vendors. This fragmented approach often leads to integration bottlenecks in which the transfer of sub-assemblies between machines creates buffer accumulation issues and increases the risk of contamination or damage.

Engineering Solution: A turnkey approach, in which a single system supplier provides both the pre-assembly and final assembly lines, eliminates these integration hurdles. This allows for a unified control architecture (e.g., a single PLC/HMI platform) and seamless physical transfer systems. By designing the line as a cohesive unit, manufacturers can implement intelligent buffering systems that dynamically adjust the speed of upstream processes based on downstream demand, maintaining a continuous flow and maximizing overall equipment effectiveness.

Challenge 4: Ensuring Compliance and Accelerating Validation

In the highly regulated pharmaceutical industry, high-speed production is meaningless without stringent quality assurance and comprehensive validation (installation qualification/operational qualification/performance qualification).5 Implementing 100% in-line inspection at 160 PPM generates massive amounts of data, which can overwhelm standard control systems.

Engineering Solution: Modern assembly lines must integrate edge computing to process vision inspection data locally, ensuring real-time pass/fail decisions without latency.6 Furthermore, adopting a quality by design approach during the engineering phase ensures that critical process parameters are continuously monitored and controlled.7 Partnering with equipment suppliers who offer comprehensive validation documentation and regulatory support significantly accelerates the factory acceptance testing/site acceptance testing processes and overall time-to-market.

Conclusion

Scaling up pen injector production to meet global demand requires overcoming significant engineering bottlenecks in component handling, precision assembly, and system integration. By adopting advanced servo-control, vision-guided feeding, and a unified turnkey approach to pre-assembly and final assembly, manufacturers can achieve stable, high-speed production. Partnering with an experienced system supplier who understands both the mechanical intricacies and the stringent regulatory requirements is essential for ensuring product quality and accelerating time-to-market in this competitive landscape.

References

1. Anselmo, A. C., & Mitragotri, S. (2014). An overview of clinical and commercial impact of drug delivery systems. Journal of Controlled Release, 190, 15-28. https://doi.org/10.1016/j.jconrel.2014.03.053

2. Perrone, M. G., & Maiocchi, M. (2022). Applying lean methodologies to improve the OEE of a manufacturing line: a case study in a pharmaceutical company. Politecnico di Milano. Retrieved from https://www.politesi.polimi.it/handle/10589/204180

3. Srai, value, S. C., Badman, C., … & Florence, A. J. (2015). Future supply chains enabled by continuous processing—opportunities and challenges. Journal of Pharmaceutical Sciences, 104(3), 840-849. https://doi.org/10.1002/jps.24343

4. Kistler Group. (2022). Efficient force-displacement monitoring and process control for medical device assembly. Assembly Show Presentation.

5.International Society for Pharmaceutical Engineering (ISPE). (2008). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems. ISPE.

6. Sharma, D., et al. (2023). A comprehensive study on Industry 4.0 in the pharmaceutical sector. Sustainable Development, PMC10153053. https://doi.org/10.1007/s10668-023-03225-8

7. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2009). ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8(R2). Retrieved from https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf

1. Anselmo, A. C., & Mitragotri, S. (2014). An overview of clinical and commercial impact of drug delivery systems. Journal of Controlled Release, 190, 15-28. https://doi.org/10.1016/j.jconrel.2014.03.053

2. Perrone, M. G., & Maiocchi, M. (2022). Applying lean methodologies to improve the OEE of a manufacturing line: a case study in a pharmaceutical company. Politecnico di Milano. Retrieved from https://www.politesi.polimi.it/handle/10589/204180

3. Srai, value, S. C., Badman, C., … & Florence, A. J. (2015). Future supply chains enabled by continuous processing—opportunities and challenges. Journal of Pharmaceutical Sciences, 104(3), 840-849. https://doi.org/10.1002/jps.24343

4. Kistler Group. (2022). Efficient force-displacement monitoring and process control for medical device assembly. Assembly Show Presentation.

5.International Society for Pharmaceutical Engineering (ISPE). (2008). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems. ISPE.

6. Sharma, D., et al. (2023). A comprehensive study on Industry 4.0 in the pharmaceutical sector. Sustainable Development, PMC10153053. https://doi.org/10.1007/s10668-023-03225-8

7. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2009). ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8(R2). Retrieved from https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf